• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Applications of Model Informed Drug Development (MIDD) in Drug Development Lifecycle and Regulatory Review.

作者信息

Mitra Amitava, Wang Yaning

机构信息

Clinical Pharmacology and Pharmacometrics, Janssen R&D, Spring House, PA, USA.

Clinical Pharmacology, Kura Oncology, San Diego, CA, USA.

出版信息

Pharm Res. 2022 Aug;39(8):1663-1667. doi: 10.1007/s11095-022-03327-6. Epub 2022 Jul 5.

DOI:10.1007/s11095-022-03327-6
PMID:35790617
Abstract
摘要

相似文献

1
Applications of Model Informed Drug Development (MIDD) in Drug Development Lifecycle and Regulatory Review.模型引导药物研发（MIDD）在药物开发生命周期和监管审评中的应用
Pharm Res. 2022 Aug;39(8):1663-1667. doi: 10.1007/s11095-022-03327-6. Epub 2022 Jul 5.
2
Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.综述：模型指导药物研发方法在药物研发和监管决策生命周期中的作用。
Pharm Res. 2022 Aug;39(8):1669-1680. doi: 10.1007/s11095-022-03288-w. Epub 2022 May 12.
3
Opportunities and challenges for applying model-informed drug development approaches to gene therapies.应用模型指导药物研发方法于基因治疗的机遇与挑战。
CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):286-290. doi: 10.1002/psp4.12597. Epub 2021 Mar 5.
4
Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future.儿科、孕期及老年药物研发中的模型引导药物研发：现状与未来
Adv Drug Deliv Rev. 2024 Aug;211:115364. doi: 10.1016/j.addr.2024.115364. Epub 2024 Jun 25.
5
Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.基于模型的抗感染药物研发：现状与未来。
Clin Pharmacol Ther. 2021 Apr;109(4):867-891. doi: 10.1002/cpt.2198. Epub 2021 Mar 9.
6
Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling.模型指导药物研发在儿科药物研发、监管评估和标签中的作用。
J Clin Pharmacol. 2019 Sep;59 Suppl 1:S104-S111. doi: 10.1002/jcph.1478.
7
Perspective on model-informed drug development.模型引导药物研发的视角。
CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1127-1129. doi: 10.1002/psp4.12699. Epub 2021 Aug 17.
8
How can natural language processing help model informed drug development?: a review.自然语言处理如何助力模型指导下的药物研发？综述
JAMIA Open. 2022 Jun 11;5(2):ooac043. doi: 10.1093/jamiaopen/ooac043. eCollection 2022 Jul.
9
Model-Informed Drug Development in Pediatric Dose Selection.基于模型的儿科剂量选择中的药物研发。
J Clin Pharmacol. 2021 Jun;61 Suppl 1:S60-S69. doi: 10.1002/jcph.1848.
10
Model-Informed Drug Development: Current US Regulatory Practice and Future Considerations.模型引导药物研发：当前美国监管实践与未来考量
Clin Pharmacol Ther. 2019 Apr;105(4):899-911. doi: 10.1002/cpt.1363. Epub 2019 Mar 1.

引用本文的文献

1
A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment.一种基于生理学的定量系统药理学模型，用于从机制上理解对阿格列汀的反应及其在肾功能损害患者中的应用。
J Pharmacokinet Pharmacodyn. 2025 Jan 16;52(1):13. doi: 10.1007/s10928-025-09961-y.
2
Editorial: Model-informed drug development and precision dosing in clinical pharmacology practice.社论：临床药理学实践中的模型引导药物研发与精准给药
Front Pharmacol. 2023 Jun 30;14:1224980. doi: 10.3389/fphar.2023.1224980. eCollection 2023.

本文引用的文献

1
The Effects of Solid Particle Containing Inks on the Printing Quality of Porous Pharmaceutical Structures Fabricated by 3D Semi-Solid Extrusion Printing.含固形物颗粒墨水对 3D 半固态挤出打印多孔药物结构打印质量的影响。
Pharm Res. 2022 Jun;39(6):1267-1279. doi: 10.1007/s11095-022-03299-7. Epub 2022 Jun 3.
2
Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application.定量系统药理学（QSP）在非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）药物开发中的应用及其监管应用。
Pharm Res. 2022 Aug;39(8):1789-1802. doi: 10.1007/s11095-022-03295-x. Epub 2022 May 24.
3
The Use of Physiologically Based Pharmacokinetic Analyses-in Biopharmaceutics Applications -Regulatory and Industry Perspectives.
基于生理学的药代动力学分析在生物药剂学应用中的应用——监管和行业视角。
Pharm Res. 2022 Aug;39(8):1681-1700. doi: 10.1007/s11095-022-03280-4. Epub 2022 May 18.
4
Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.基于生理药代动力学建模和模拟的应用、挑战与展望：监管、工业和学术视角。
Pharm Res. 2022 Aug;39(8):1701-1731. doi: 10.1007/s11095-022-03274-2. Epub 2022 May 13.
5
Role of Disease Progression Models in Drug Development.疾病进展模型在药物研发中的作用。
Pharm Res. 2022 Aug;39(8):1803-1815. doi: 10.1007/s11095-022-03257-3. Epub 2022 Apr 11.
6
Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients.基于项目的药代动力学模型在确证性研究阶段的应用提高了置信度：以 COPD 患者的 III 期阳性对照临床试验为例。
Pharm Res. 2022 Aug;39(8):1779-1787. doi: 10.1007/s11095-022-03194-1. Epub 2022 Mar 1.